Monoclonal PCSK9 antibodies are already on the market and small interfering RNAs studied as potentially effective drugs against hypercholesterolemia (Lloyd-Jones et al., 2017; Momtazi et al., 2017; Stoekenbroek et al., 2018). This evidence concerns the gene PCSK9 and Hypercholesterolemia.